Hyper-IgD syndrome (HIDS) or Mevalonate Kinase Deficiency (MKD)
MKD is a rare genetic autoinflammatory disorder. Hyper-IgD syndrome is the less severe and more common form of MKD, characterized by recurrent episodes of unexplained fever. HIDS is caused by mutations in the gene MVK which encodes the enzyme mevalonate kinase.
The first flare usually takes place during infancy. There is often an abrupt onset of fever with no associated infection. Most flares occur approximately every four to six weeks, lasting from three to seven days, and occur periodically throughout life. The frequency of episodes and their severity vary greatly from person to person.
These episodes/flares are accompanied by:
- joint inflammation (arthritis)
- abdominal pain
- swelling of affected lymph nodes (lymphadenopathy)
Additional symptoms include:
- mouth ulcers
- enlargement of the liver & spleen
The rash consists of reddish (erythematous) spots (macules) or bumps (papules). Some individuals have a cough and inflammation of the back of the throat (pharyngitis).
HIDS is often more severe in children. Affected children often have a high spiking fever that, in some instances, can cause convulsions. Children are also more likely to have an abnormally enlarged spleen. Flares can occur spontaneously or be triggered by vaccinations, infections, and/or emotional or physical stress. Growth and development are usually not affected, unlike in patients with more severe disease mevalonic aciduria, MVA). Adults may have mood and psychiatric features including depression.
Most people with the disorder are individuals of western European heritage with approximately 60% occurring in Dutch or French individuals.
A diagnosis is made based upon a thorough clinical evaluation, identification of characteristic symptoms (e.g., recurrent fevers not caused by infection), and a variety of tests including blood tests to determine the levels of immunoglobulin D (IgD) in the blood, urine tests to detect the presence of mevalonate kinase, and DNA analysis to detect the genetic mutation associated with the disorder.
High levels of immunoglobulin D (IgD) is indicative of mevalonate kinase deficiency but does not confirm a diagnosis. Some individuals do not show this finding and their IgD levels may be normal. Also, other periodic fever syndromes may have high levels of IgD in the blood.
A blood test of the inflammatory markers such as erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), serum amyloid protein A (SAA), and a complete blood count & fibrinogen can be performed during a flare to determine the extent of the inflammation. When the flare is over, the blood test can be done again to see if the inflammatory markers have returned to normal or almost back to normal.
A urine sample is also examined to detect the presence of protein and red blood cells. During flares, these may temporarily increase significantly. Patients with amyloidosis, however, have permanently elevated protein concentrations in the urine.
Acute episodes may be triggered by:
Vaccinations – more than 50% report at least one episode in childhood following an immunisation
Physical and emotional stress
Trauma, including surgery
Dos Santos Sobrín R, Lopez-Montesinos B, Martí Masanet M, et alAB0979 Mevalonate Kinase Deficiency at Treatment with Canakinumab: Rare Belated Cutaneous Feature. Annals of the Rheumatic Diseases 2020;79:1784. https://ard.bmj.com/content/79/Suppl_1/1784.2
Petryna O., Purat N. (2019) Mevalonate Kinase Deficiency (MKD)/Hyperimmunoglobulin D Syndrome (HIDS). In: Efthimiou P. (eds) Auto-Inflammatory Syndromes. Springer, Cham. https://doi.org/10.1007/978-3-319-96929-9_2
Mulders-Manders, C.M., Simon, A. Hyper-IgD syndrome/mevalonate kinase deficiency: what is new?. Semin Immunopathol 37, 371–376 (2015). https://doi.org/10.1007/s00281-015-0492-6
Stoffels, Monique; Simon, Anna Hyper-IgD syndrome or mevalonate kinase deficiency, Current Opinion in Rheumatology: September 2011 - Volume 23 - Issue 5 - p 419-423 https://journals.lww.com/co-rheumatology/Abstract/2011/09000/Hyper_IgD_syndrome_or_mevalonate_kinase_deficiency.3.aspx
Pınar Gençpınar, Balahan B. Makay, Marco Gattorno, Francesco Caroli, Erbil Ünsal. Mevalonate kinase deficiency (hyper IgD syndrome with periodic fever) - different faces with separate treatments: two cases and review of the literature. The Turkish Journal of Pediatrics 2012; 54: 641-644. https://www.researchgate.net/profile/Francesco-Caroli/publication/236926937_Mevalonate_Kinase_Deficiency_Hyper_IgD_Syndrome_with_Periodic_Fever_-_Different_Faces_with_Separate_Treatments_Two_Cases_and_Review_of_the_Literature/links/0c960539e2646971c4000000/Mevalonate-Kinase-Deficiency-Hyper-IgD-Syndrome-with-Periodic-Fever-Different-Faces-with-Separate-Treatments-Two-Cases-and-Review-of-the-Literature.pdf
Sander M. Houten, Joost Frenkel, Ger T. Rijkers, Ronald J.A. Wanders, Wietse Kuis, Hans R. Waterham, Temperature dependence of mutant mevalonate kinase activity as a pathogenic factor in Hyper-IgD and periodic fever syndrome, Human Molecular Genetics, Volume 11, Issue 25, 1 December 2002, Pages 3115–3124, https://doi.org/10.1093/hmg/11.25.3115
De Benedetti F, Gattorno M, Anton J, Ben-Chetrit E, Frenkel J, Hoffman HM, Koné-Paut I, Lachmann HJ, Ozen S, Simon A, Zeft A, Calvo Penades I, Moutschen M, Quartier P, Kasapcopur O, Shcherbina A, Hofer M, Hashkes PJ, Van der Hilst J, Hara R, Bujan-Rivas S, Constantin T, Gul A, Livneh A, Brogan P, Cattalini M, Obici L, Lheritier K, Speziale A, Junge G. Canakinumab for the Treatment of Autoinflammatory Recurrent Fever Syndromes. N Engl J Med. 2018 May 17;378(20):1908-1919. https://pubmed.ncbi.nlm.nih.gov/29768139/
ter Haar NM, Oswald M, Jeyaratnam J, et alRecommendations for the management of autoinflammatory diseases. Annals of the Rheumatic Diseases 2015;74:1636-1644. https://ard.bmj.com/content/74/9/1636
Mevalonate Kinase Deficiency by Grant S Schulert. MD for NORD
Hyper-IgD syndrome, NIH - GARD